Phase II study of pemetrexed and carboplatin plus bevacizumab with maintenance pemetrexed and bevacizumab for Japanese nonsquamous non-small cell lung cancer

被引：0
|
作者：
Yokoi, Takashi [1 ]
Torii, Yoshitaro [1 ]
Katashiba, Yuichi [1 ]
Sugimoto, Hiroyuki [1 ]
Hayashi, Mina [1 ]
Shimizu, Toshiki [1 ]
Nomura, Shosaku [1 ]
机构：
[1] Kansai Med Univ, Dept Internal Med 1, Osaka, Japan
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2012年 / 30卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e18081
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase II study of pemetrexed and carboplatin plus bevacizumab, followed by maintenance pemetrexed and bevacizumab in Japanese patients with non-squamous non-small cell lung cancer
    Yokoi, Takashi
    Torii, Yoshitaro
    Katashiba, Yuichi
    Sugimoto, Hiroyuki
    Tanijiri, Tsutomu
    Ogata, Makoto
    Inagaki, Noriko
    Kibata, Kayoko
    Hayashi, Mina
    Niki, Maiko
    Shimizu, Toshiki
    Miyara, Takayuki
    Kurata, Takayasu
    Nomura, Shosaku
    [J]. ONCOLOGY LETTERS, 2014, 8 (06) : 2453 - 2457
  • [2] Phase II Study of Pemetrexed and Carboplatin Plus Bevacizumab With Maintenance Pemetrexed and Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer
    Patel, Jyoti D.
    Hensing, Thomas A.
    Rademaker, Alfred
    Hart, Eric M.
    Blum, Matthew G.
    Milton, Daniel T.
    Bonomi, Philip D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (20) : 3284 - 3289
  • [3] A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed or Bevacizumab Plus Pemetrexed for Advanced Non-squamous Non-small Cell Lung Cancer
    Yoshida, Hironori
    Kim, Young Hak
    Sakamori, Yuichi
    Nagai, Hiroki
    Ozasa, Hiroaki
    Kaneda, Toshihiko
    Yoshioka, Hiroshige
    Nakagawa, Hiroaki
    Tomii, Keisuke
    Okada, Asuka
    Yoshimura, Kenichi
    Hirabayashi, Masataka
    Hirai, Toyohiro
    [J]. ANTICANCER RESEARCH, 2020, 40 (05) : 2981 - 2987
  • [4] Phase II trial of bevacizumab plus pemetrexed and carboplatin in previously untreated advanced nonsquamous non-small cell lung cancer
    Dalsania, C. J.
    Hageboutros, A.
    Harris, E.
    Krieger, K.
    Vora, C.
    Stevenson, J.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [5] Phase II study of carboplatin, pemetrexed, and bevacizumab in advanced nonsquamous non-small-cell lung cancer
    Laslett, Nicole F.
    Park, Sujung
    Masters, Gregory A.
    Biggs, David D.
    Schneider, Charles J.
    Misleh, Jamal G.
    Suppiah, Kathir
    Simpson, Pamela S.
    Grubbs, Stephen
    Wozniak, Timothy F.
    Guarino, Michael
    [J]. CANCER MEDICINE, 2018, 7 (07): : 2969 - 2973
  • [6] A Randomized Phase II Study of Maintenance Bevacizumab, Pemetrexed, or Bevacizumab plus Pemetrexed in Advanced Nonsquamous Non-Small Cell Lung Cancer (Kyoto Thoracic Oncology Research Group 1101)
    Kaneda, T.
    Yoshida, H.
    Sakamori, Y.
    Nagai, H.
    Ozasa, H.
    Hirai, T.
    Yoshioka, H.
    Nakagawa, H.
    Tomii, K.
    Okada, A.
    Yoshimura, K.
    Hirabayashi, M.
    Kim, Y. H.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
  • [7] PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
    Patel, Jyoti D.
    Socinski, Mark A.
    Garon, Edward B.
    Reynolds, Craig H.
    Spigel, David R.
    Olsen, Mark R.
    Hermann, Robert C.
    Jotte, Robert M.
    Beck, Thaddeus
    Richards, Donald A.
    Guba, Susan C.
    Liu, Jingyi
    Frimodt-Moller, Bente
    John, William J.
    Obasaju, Coleman K.
    Pennella, Eduardo J.
    Bonomi, Philip
    Govindan, Ramaswamy
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (34) : 4349 - U77
  • [8] Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
    Tsutani, Yasuhiro
    Miyata, Yoshihiro
    Masuda, Takeshi
    Fujitaka, Kazunori
    Doi, Mihoko
    Awaya, Yoshikazu
    Kuyama, Shoichi
    Kitaguchi, Soichi
    Ueda, Kazuhiro
    Hattori, Noboru
    Okada, Morihito
    [J]. BMC CANCER, 2018, 18
  • [9] Multicenter phase II study on cisplatin, pemetrexed, and bevacizumab followed by maintenance with pemetrexed and bevacizumab for patients with advanced or recurrent nonsquamous non-small cell lung cancer: MAP study
    Yasuhiro Tsutani
    Yoshihiro Miyata
    Takeshi Masuda
    Kazunori Fujitaka
    Mihoko Doi
    Yoshikazu Awaya
    Shoichi Kuyama
    Soichi Kitaguchi
    Kazuhiro Ueda
    Noboru Hattori
    Morihito Okada
    [J]. BMC Cancer, 18
  • [10] EXPLORATORY SUBSET ANALYSIS IN AFRICAN AMERICANS FROM THE POINTBREAK STUDY (RANDOMIZED PHASE 3 PEMETREXED plus CARBOPLATIN plus BEVACIZUMAB FOLLOWED BY MAINTENANCE PEMETREXED plus BEVACIZUMAB VERSUS PACLITAXEL plus CARBOPLATIN plus BEVACIZUMAB FOLLOWED BY MAINTENANCE BEVACIZUMAB IN PATIENTS WITH STAGE IIIB/IV NONSQUAMOUS NON-SMALL CELL LUNG CANCER)
    Reynolds, Craig
    Patel, Jyoti D.
    Garon, Edward
    Olsen, Mark R.
    Bonomi, Philip
    Govindan, Ramaswamy
    Obasaju, Coleman
    Pennella, Eduardo J.
    Liu, Jingyi
    Guba, Susan C.
    Spigel, David
    Hermann, Robert C.
    Socinski, Mark A.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S562 - S562
12345